Cocrystal Pharma, Inc. Share Price & Technical Analysis
COCP · $1.15 (+1.77%)
Healthcare / Biotechnology
$1.15
+1.77%
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepa…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
-27% return in May, 14% avg return in past 3 year May month.
13% return in 2026, -12% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 0% | 0% | 0% | 40% | -27% | – | – | – | – | – | – | – | 13% |
| 25 | -9% | -15% | -22% | 7% | 13% | -12% | 13% | -17% | -20% | -8% | 0% | -9% | -78% |
| 24 | -6% | -12% | 0% | 0% | 38% | 5% | -17% | -5% | 0% | 6% | 17% | -5% | 19% |
| 23 | 47% | -29% | 0% | 25% | -8% | 9% | 13% | 15% | -39% | -11% | 12% | -11% | 24% |
| 22 | -14% | -3% | 0% | -16% | -14% | -2% | 0% | -2% | -29% | -22% | 4% | -26% | -124% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is a phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, an HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was headquartered in Bothell, Washington.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$17.85M
P/E ratio
—
52W high
$2.67
52W low
$0.86
Volume
54,413
Beta
1.50
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Cocrystal Pharma, Inc. share price today?
- Cocrystal Pharma, Inc. (COCP) last traded around $1.15 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does COCP have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for COCP. Download the app for real-time alerts.
- How can I analyze Cocrystal Pharma, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.